A Low-Sodium Diet Potentiates the Effects of Losartan in Type 2 Diabetes

A Low-Sodium Diet Potentiates the Effects of Losartan in Type 2 Diabetes Christine A. Houlihan , MBBS 1 , Terri J. Allen , PHD 1 , Amynta L. Baxter , BSC, MHN 1 , Sianna Panangiotopoulos , PHD 1 , David J. Casley , M APP SC 2 , Mark E. Cooper , MBBS, PHD 1 and George Jerums , MBBS, MD 1 1 Endocrine...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes care Vol. 25; no. 4; pp. 663 - 671
Main Authors: HOULIHAN, Christine A, ALLEN, Terri J, BAXTER, Amynta L, PANANGIOTOPOULOS, Sianna, CASLEY, David J, COOPER, Mark E, JERUMS, George
Format: Journal Article
Language:English
Published: Alexandria, VA American Diabetes Association 01-04-2002
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A Low-Sodium Diet Potentiates the Effects of Losartan in Type 2 Diabetes Christine A. Houlihan , MBBS 1 , Terri J. Allen , PHD 1 , Amynta L. Baxter , BSC, MHN 1 , Sianna Panangiotopoulos , PHD 1 , David J. Casley , M APP SC 2 , Mark E. Cooper , MBBS, PHD 1 and George Jerums , MBBS, MD 1 1 Endocrine Unit and Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia 2 Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia Abstract OBJECTIVE —Diabetic subjects have a high prevalence of hypertension, increased total body exchangeable sodium levels, and an impaired ability to excrete a sodium load. This study assessed the effect of dietary sodium restriction on the efficacy of losartan in hypertensive subjects with type 2 diabetes and albumin excretion rates of 10–200 μg/min. RESEARCH DESIGN AND METHODS —In this study, 20 subjects were randomized to losartan 50 mg/day ( n = 10) or placebo ( n = 10). Drug therapy was given in two 4-week phases separated by a washout period. In the last 2 weeks of each phase, patients were assigned to low- or regular-sodium diets, in random order. In each phase, 24-h ambulatory blood pressure, urinary albumin-to-creatinine ratio (ACR), and renal hemodynamics were measured. RESULTS —Achieved urinary sodium on a low-sodium diet was 85 ± 14 and 80 ± 22 mmol/day in the losartan and placebo groups, respectively. In the losartan group, the additional blood pressure-lowering effects of a low-sodium diet compared with a regular-sodium diet for 24-h systolic, diastolic, and mean arterial blood pressures were 9.7 mmHg (95% confidence interval [CI], 2.2−17.2; P = 0.002), 5.5 mmHg (2.6−8.4; P = 0.002), and 7.3 mmHg (3.3− 11.3; P = 0.003), respectively. In the losartan group, the ACR decreased significantly on a low-sodium diet versus on a regular-sodium diet (−29% [CI −50.0 to −8.5%] vs. + 14% [−19.4 to 47.9%], respectively; P = 0.02). There was a strong correlation between fall in blood pressure and percent reduction in the ACR ( r = 0.7, P = 0.02). In the placebo group, there were no significant changes in blood pressure or ACR between regular- and low-sodium diets. There were no significant changes in renal hemodynamics in either group. CONCLUSIONS —These data demonstrated that a low-sodium diet potentiates the antihypertensive and antiproteinuric effects of losartan in type 2 diabetes. The blood pressure reduction resulting from the addition of a low-sodium diet to losartan was of similar magnitude to that predicted from the addition of a second antihypertensive agent. Footnotes Address correspondence and reprint requests to Prof. George Jerums, Endocrine Unit, Austin and Repatriation Medical Centre, Studley Rd., Heidelberg 3084, Victoria, Australia. E-mail: endo{at}austin.unimelb.edu.au . Received for publication and accepted in revised form. Abbreviations: ABP, ambulatory blood pressure; ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; ANG, angiotensin; CI, confidence interval; ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; PAH, para-aminohippurate; P GC , glomerular capillary pressure; PRA, plasma renin activity; RAS, renin-angiotensin system. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. M.E.C. is on an advisory panel for Merck on diabetic nephropathy, he has received honoraria for speaking engagements for Merck, and his laboratory has received funding from Merck for studies on a new drug to treat retinopathy. DIABETES CARE
ISSN:0149-5992
1935-5548
DOI:10.2337/diacare.25.4.663